Literature DB >> 27453422

Long noncoding ribonucleic acids maternally expressed gene 3 inhibits lung cancer tumor progression through downregulation of MYC.

L Yan-Hua1, L Xiang-Lei1, L Hong1, W Jian-Jun1.   

Abstract

OBJECTIVE: Long noncoding ribonucleic acids (RNAs) nowadays emerge as important biomarkers or potential therapeutic targets discussed in human cancers. Among them, maternally expressed gene 3 (MEG3) is known to be decreased in a variety of malignancies.
MATERIALS AND METHODS: Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was performed to detect the expression of MEG3 in forty pairs of lung cancer (LC) tissues. Overexpression of MEG3 was carried out, and we determined its effect on cell proliferation, apoptosis, and migration evaluated by cell counting kit-8, flow cytometric, and transwell analysis. Messenger RNA and protein expression of MYC were determined by qRT-PCR and western blot, respectively.
RESULTS: The expression of MEG3 was downregulated in LC tissues. Forced expression of MEG3 led to reduced abilities of cell proliferation and elevated apoptosis rate. It also slightly inhibited cell migration capacity in vitro. In addition, MYC was inhibited by MEG3 overexpression at both transcriptional and translational levels.
CONCLUSION: Our findings revealed MEG3 could regulate LC progression and serve as an important target for LC treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27453422     DOI: 10.4103/0019-509X.186579

Source DB:  PubMed          Journal:  Indian J Cancer        ISSN: 0019-509X            Impact factor:   1.224


  6 in total

1.  LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis.

Authors:  Pei Wang; Dong Chen; Hongbing Ma; Yong Li
Journal:  Onco Targets Ther       Date:  2017-10-25       Impact factor: 4.147

2.  Identification and validation a TGF-β-associated long non-coding RNA of head and neck squamous cell carcinoma by bioinformatics method.

Authors:  Teng Huang; Wei Huang; Hong Lu; Bi-Yun Zhang; Jun Ma; Di Zhao; Yi-Jun Wang; Da-Hai Yu; Xia He
Journal:  J Transl Med       Date:  2018-02-28       Impact factor: 5.531

3.  Tunicamycin inhibits progression of glioma cells through downregulation of the MEG-3-regulated wnt/β-catenin signaling pathway.

Authors:  Xin Li; Lei Xue; Qin Peng
Journal:  Oncol Lett       Date:  2018-04-03       Impact factor: 2.967

4.  MEG-3-mediated Wnt/β-catenin signaling pathway controls the inhibition of tunicamycin-mediated viability in glioblastoma.

Authors:  Xiangyu Cui; Dezhou Sun; Bin Shen; Xin Wang
Journal:  Oncol Lett       Date:  2018-06-28       Impact factor: 2.967

5.  Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes.

Authors:  Dries Rombaut; Hua-Sheng Chiu; Bieke Decaesteker; Celine Everaert; Nurten Yigit; Agathe Peltier; Isabelle Janoueix-Lerosey; Christoph Bartenhagen; Matthias Fischer; Stephen Roberts; Nicky D'Haene; Katleen De Preter; Frank Speleman; Geertrui Denecker; Pavel Sumazin; Jo Vandesompele; Steve Lefever; Pieter Mestdagh
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

6.  MEG3 promotes proliferation and inhibits apoptosis in osteoarthritis chondrocytes by miR-361-5p/FOXO1 axis.

Authors:  Anying Wang; Naixia Hu; Yefeng Zhang; Yuanzhen Chen; Changhui Su; Yao Lv; Yong Shen
Journal:  BMC Med Genomics       Date:  2019-12-30       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.